For thousands of years, the coca leaf was medicine. Then the Drug War made a plant into a villain. It's time to rethink what we've been told.
The coca leaf — Erythroxylum coca — has been chewed, brewed, and revered by Andean cultures for over 8,000 years. It is a mild stimulant, comparable in effect to a strong cup of coffee. It suppresses altitude sickness, reduces fatigue, and sharpens focus. Millions of people in Bolivia, Peru, and Colombia use it daily.
Refined cocaine hydrochloride is a concentrated alkaloid extract that delivers a massive, rapid dopamine surge. It is as different from the coca leaf as morphine is from poppy seed tea, or methamphetamine is from an Ephedra plant.
The Drug War collapsed this distinction. Policy treated the leaf and the powder as the same thing. That was a scientific error with catastrophic human consequences.
Cocaine is a dopamine-norepinephrine-serotonin reuptake inhibitor. In plain language: it increases the availability of neurotransmitters associated with focus, motivation, and alertness. This is the exact same mechanism used by the most commonly prescribed ADHD medications in the world.
The critical variable isn't the mechanism — it's the delivery speed. Ritalin works because it's slow-release. The coca leaf is naturally slow-release. Refined cocaine is dangerous because it hits fast and leaves fast, creating the binge cycle. The plant solved this problem thousands of years before pharmaceutical companies did.
Approximately 366 million adults worldwide have ADHD. Most are undiagnosed. Most are unmedicated. Those who do get treatment face a pharmaceutical system designed around synthetic stimulants — Adderall, Ritalin, Vyvanse — that carry side effects including insomnia, appetite loss, cardiovascular strain, and dependency.
The global ADHD medication market was valued at over $24 billion in 2024. It is projected to reach $40+ billion by 2030. This entire industry is built on synthetic versions of what a plant does naturally.
A standardized coca-leaf extract — dosed in tablets, capsules, or gummies — would function as a natural, plant-based ADHD therapeutic. Lower cost. Fewer synthetic additives. A gentler pharmacological profile buffered by the leaf's full alkaloid spectrum. The plant already delivers what the pills are trying to replicate.
Imagine a world where a person with ADHD could take a standardized 50mg coca-leaf extract gummy — produced under pharmaceutical-grade quality control in Colombia — and experience 2–3 hours of clean, natural focus. No jitters. No crash. No dependency spiral. No $400/month prescription.
This isn't science fiction. The pharmacology supports it. The agricultural infrastructure exists. The traditional knowledge is there. The only thing standing in the way is 50 years of policy built on the failure to distinguish between a leaf and a powder.
In 2016, the DEA announced its intent to classify kratom — a Southeast Asian plant that acts on opioid receptors — as a Schedule I controlled substance. The public backlash was so fierce that the DEA withdrew its proposal. Today, kratom is a multi-billion dollar industry in the United States.
The kratom playbook is the coca playbook. The parallels are exact.
Kratom: Chewed by Thai and Malaysian laborers for centuries as a mild stimulant and pain reliever. Coca: Chewed by Andean peoples for 8,000+ years for energy, altitude sickness, and focus.
Kratom: Associated with opioid addiction despite being used by many as an opioid withdrawal aid. Coca: Conflated with refined cocaine despite the leaf being pharmacologically distinct.
Kratom: DEA's 2016 scheduling attempt met with 23,000+ public comments and congressional pushback. Coca: The UN Single Convention on Narcotic Drugs (1961) scheduled the coca leaf alongside refined cocaine — a classification Bolivia formally objected to in 2011.
Kratom: Now sold as capsules, powders, extracts, gummies, and drinks in every US state without a specific ban. Multi-billion dollar industry. Coca: Still waiting. Coca tea, coca flour, and coca energy products exist legally in Bolivia and Peru but cannot reach international markets.
Kratom proved that a "dangerous" plant could become a mainstream wellness product when people were allowed to use it responsibly. The same path is open for coca. Colombia should be leading this market — not burning the crops.
Colombia has everything it needs to lead the global standardized coca therapeutics market: the agricultural expertise, the growing conditions, the traditional knowledge, the pharmaceutical manufacturing capacity, and — increasingly — the political will for drug policy reform.
The question isn't whether coca-based wellness products will eventually reach international markets. The question is who will build the industry — and whether Colombia will lead it or let Bolivia and Peru get there first.
Colombia's current administration has signaled openness to rethinking drug policy — moving away from forced eradication and toward crop substitution, decriminalization, and recognition of indigenous coca traditions. The country already has pharmaceutical manufacturing infrastructure capable of producing standardized botanical extracts to international quality standards.
The opportunity is to position Colombia not as the source of a problem, but as the home of a solution. A standardized, quality-controlled, plant-based focus supplement — produced ethically, tested clinically, and marketed honestly — could transform coca from Colombia's greatest stigma into its most valuable export.
Advocating for the medicalization of the coca leaf does not mean ignoring the realities of refined cocaine. Cocaine addiction is real. Cocaine-related deaths are real. The violence of the drug trade is real. Any honest conversation about coca must acknowledge these facts.
Our position is that prohibition has made all of these problems worse, and that distinguishing between the plant and the product is the first step toward rational policy.
We advocate for the medicalization and standardization of coca leaf products. We do not advocate for the legalization of refined cocaine hydrochloride.
As with caffeine, alcohol, and every other psychoactive substance, the danger of coca is a function of concentration, delivery speed, and dosing — not the plant itself.
The Drug War hasn't eliminated coca — it has militarized farming communities, filled prisons, funded cartels, and prevented clinical research into the leaf's legitimate therapeutic potential.
We support properly funded clinical trials into standardized coca-leaf extracts for focus, energy, and ADHD management. Policy should follow evidence, not fear.
From Incan runners to Bolivian miners, the story of humanity's longest relationship with a stimulant plant.
The kratom industry went from scheduling threat to billion-dollar market in under a decade. Here's the playbook.
A pharmacological comparison of ADHD stimulants and the coca leaf — and why one is a felony.
Research, policy analysis, and dispatches from the frontlines of coca reform — delivered to your inbox.